Physician
New York City Health and Hospitals Corporation
New York City Health and Hospitals Corporation was paid $146.57M by Medicaid between Jan 2018 and Dec 2024, across 610 billing codes. Its largest line is 99283, emergency room visit (moderate) — 11% of everything it billed.
33Billing provider infoNEW YORK CITY HEALTH AND HOSPITALS CORPORATION
ELMHURST, NY 11373
ELMHURST, NY 11373
33aNPI1063426377assigned 07/29/2006
33bProvider typeInternal Medicine Physician
28Total paid$146.57M
24GClaims3,455,689
24DCodes billed610
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in New York
Rank by total paid#5 of 6,049
Median peer was paid$11K
This provider vs. median12,956×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KARLIN, MARJI controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 101,740 | $428K | |
| 2019 | 257,342 | $8.73M | |
| 2020 | 520,401 | $22.85M | |
| 2021 | 852,266 | $35.36M | |
| 2022 | 749,231 | $34.81M | |
| 2023 | 528,377 | $23.94M | |
| 2024incomplete | 446,332 | $20.46M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 80,286 | 75,782 | $15.60M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9.1% | 197,149 | 171,834 | $13.30M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.6% | 44,701 | 42,611 | $9.74M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.5% | 42,435 | 39,739 | $8.10M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.1% | 67,420 | 61,514 | $7.50M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5.0% | 110,099 | 96,373 | $7.35M |
| 36415 | Collection of venous blood by venipuncture | 3.4% | 326,835 | 142,813 | $4.99M |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 3.4% | 10,085 | 9,001 | $4.94M |
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 3.0% | 124,133 | 10,761 | $4.42M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 3.0% | 33,475 | 19,002 | $4.38M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.0% | 53,527 | 47,756 | $2.97M |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 1.8% | 15,832 | 8,040 | $2.57M |
598 more codes
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.4% | 109,130 | $1.99M |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | 1.2% | 9,614 | $1.76M |
| 81408 | 1.1% | 1,150 | $1.59M | |
| 99204 | Doctor's office visit, new patient (more involved) | 1.1% | 9,667 | $1.57M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.1% | 45,397 | $1.55M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.0% | 39,638 | $1.51M |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 5,741 | $1.19M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 25,451 | $1.16M |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 1,630 | $1.16M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 10,047 | $1.13M |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 10,009 | $1.12M |
| 99285 | Emergency room visit (most serious) | <1% | 5,677 | $1.03M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 15,439 | $983K |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 7,884 | $965K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 2,172 | $964K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 46,500 | $953K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 5,690 | $878K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 14,612 | $874K |
| G0378 | Hospital observation service, per hour | <1% | 736 | $872K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,581 | $688K |
| 99442 | <1% | 19,346 | $686K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 29,743 | $651K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 20,951 | $642K |
| 99201 | <1% | 8,519 | $636K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 7,100 | $609K |
| 99205 | Prolong outpt/office vis | <1% | 2,977 | $600K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 5,260 | $562K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 25,617 | $547K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 57,423 | $493K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 3,236 | $490K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 17,968 | $487K |
| 99443 | <1% | 8,660 | $479K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 58,955 | $475K |
| 86480 | <1% | 8,280 | $474K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 5,512 | $463K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,852 | $457K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 418 | $451K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 3,343 | $451K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 47,578 | $417K |
| H2010 | Comprehensive medication services, per 15 minutes | <1% | 5,565 | $411K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,105 | $410K |
| 59025 | Fetal non-stress test | <1% | 4,818 | $409K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,532 | $407K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 1,849 | $397K |
| 85027 | <1% | 103,616 | $374K | |
| 99441 | <1% | 14,979 | $364K | |
| G0397 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes | <1% | 2,229 | $361K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,441 | $345K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 7,115 | $341K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,883 | $319K |
| 80053 | Comprehensive metabolic panel | <1% | 28,946 | $313K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 3,872 | $303K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 29,237 | $299K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 19,123 | $295K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,028 | $294K |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 31,792 | $292K |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 4,408 | $290K |
| 0002A | <1% | 9,212 | $290K | |
| H0001 | Alcohol and/or drug assessment | <1% | 1,622 | $289K |
| 90651 | <1% | 3,584 | $288K | |
| 0001A | <1% | 11,170 | $282K | |
| D0999 | Unspecified diagnostic procedure, by report | <1% | 1,739 | $278K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,301 | $265K |
| 80061 | Lipid panel | <1% | 26,601 | $262K |
| 86703 | <1% | 20,678 | $262K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 22,979 | $261K |
| 87536 | <1% | 2,860 | $258K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 36,989 | $249K |
| 76801 | <1% | 1,906 | $245K | |
| 90461 | <1% | 23,035 | $242K | |
| 12001 | <1% | 1,092 | $236K | |
| 86850 | <1% | 14,366 | $233K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,529 | $229K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,154 | $227K |
| 81161 | <1% | 1,076 | $224K | |
| 90715 | <1% | 9,454 | $221K | |
| 12011 | <1% | 1,067 | $218K | |
| 81329 | <1% | 1,747 | $215K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,257 | $213K |
| 81405 | <1% | 1,008 | $210K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 954 | $208K |
| 76641 | <1% | 1,813 | $207K | |
| 80076 | <1% | 31,961 | $206K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 5,210 | $205K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,694 | $198K |
| 70486 | <1% | 1,448 | $197K | |
| 76770 | <1% | 1,361 | $196K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,262 | $190K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 10,793 | $190K |
| 90677 | <1% | 2,431 | $187K | |
| 83655 | <1% | 17,010 | $187K | |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 162 | $183K |
| 0004A | <1% | 4,745 | $179K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 708 | $171K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,547 | $170K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,941 | $169K |
| 86769 | <1% | 5,334 | $163K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,084 | $163K |
| 99051 | <1% | 16,553 | $158K | |
| 86360 | <1% | 3,307 | $155K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,714 | $149K |
| 81361 | <1% | 1,173 | $144K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,442 | $144K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 2,884 | $140K |
| S9485 | Crisis intervention mental health services, per diem | <1% | 109 | $136K |
| 86901 | <1% | 13,990 | $132K | |
| 92558 | <1% | 20,391 | $131K | |
| 90674 | <1% | 6,827 | $129K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,635 | $127K |
| 86359 | <1% | 3,326 | $122K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,627 | $122K |
| 77066 | Tomosynthesis, mammo | <1% | 752 | $119K |
| 92582 | <1% | 1,260 | $119K | |
| 90750 | <1% | 1,453 | $118K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 752 | $115K |
| 86803 | <1% | 10,739 | $111K | |
| 81401 | <1% | 1,172 | $111K | |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 1,792 | $111K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 818 | $110K |
| V2632 | Posterior chamber intraocular lens | <1% | 656 | $110K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 15,449 | $109K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 3,371 | $106K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,903 | $105K |
| 92567 | <1% | 4,764 | $104K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 402 | $103K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 601 | $102K |
| 90686 | <1% | 15,038 | $102K | |
| 81003 | <1% | 46,646 | $101K | |
| 12002 | <1% | 476 | $99K | |
| 97802 | <1% | 3,423 | $98K | |
| 86900 | <1% | 13,984 | $97K | |
| 72131 | <1% | 670 | $97K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,419 | $96K |
| 96367 | <1% | 2,240 | $93K | |
| 90746 | <1% | 1,715 | $93K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,418 | $92K |
| 81243 | <1% | 2,289 | $92K | |
| 92579 | <1% | 1,753 | $91K | |
| 81257 | <1% | 1,236 | $91K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 495 | $85K |
| 87340 | <1% | 10,891 | $85K | |
| 82728 | <1% | 7,638 | $84K | |
| 84439 | <1% | 11,188 | $82K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,362 | $82K |
| 59425 | <1% | 1,239 | $81K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18,215 | $81K |
| 88142 | <1% | 3,628 | $80K | |
| 93458 | <1% | 65 | $73K | |
| 90480 | <1% | 2,000 | $72K | |
| 82951 | <1% | 6,173 | $72K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 860 | $70K |
| 0072A | <1% | 1,776 | $69K | |
| 92557 | <1% | 1,728 | $69K | |
| 90697 | <1% | 4,498 | $68K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 11,572 | $67K |
| 76820 | <1% | 1,435 | $66K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 2,459 | $65K |
| 82805 | <1% | 7,071 | $64K | |
| 0071A | <1% | 1,851 | $63K | |
| 96161 | <1% | 11,463 | $63K | |
| 92250 | <1% | 1,906 | $60K | |
| D9999 | Unspecified adjunctive procedure, by report | <1% | 448 | $59K |
| 99408 | <1% | 969 | $57K | |
| 90670 | <1% | 6,540 | $57K | |
| 82607 | <1% | 5,497 | $57K | |
| J0401 | Injection, aripiprazole (abilify maintena), 1 mg | <1% | 347 | $56K |
| 73610 | <1% | 2,889 | $54K | |
| 84703 | <1% | 18,810 | $54K | |
| 73630 | <1% | 2,583 | $51K | |
| 87535 | <1% | 1,486 | $51K | |
| 81400 | <1% | 1,137 | $51K | |
| 76536 | <1% | 456 | $50K | |
| 86706 | <1% | 6,292 | $49K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 278 | $47K |
| 81255 | <1% | 1,154 | $47K | |
| 82948 | <1% | 21,825 | $47K | |
| 90734 | <1% | 1,502 | $47K | |
| 86780 | <1% | 4,269 | $46K | |
| 76642 | <1% | 496 | $46K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,426 | $45K |
| 96127 | <1% | 24,327 | $45K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 358 | $44K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 520 | $44K |
| 86762 | <1% | 3,615 | $44K | |
| 73110 | <1% | 2,643 | $44K | |
| 81251 | <1% | 1,153 | $43K | |
| 81200 | <1% | 1,154 | $43K | |
| 83880 | <1% | 2,867 | $43K | |
| 92134 | <1% | 941 | $41K | |
| 73564 | <1% | 1,780 | $41K | |
| 76818 | <1% | 357 | $41K | |
| 90732 | <1% | 458 | $40K | |
| 82105 | <1% | 2,930 | $40K | |
| 86765 | <1% | 3,624 | $40K | |
| 85610 | <1% | 14,644 | $39K | |
| H0049 | Alcohol and/or drug screening | <1% | 673 | $39K |
| 99381 | <1% | 5,565 | $39K | |
| 81025 | <1% | 6,198 | $38K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 217 | $38K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 68 | $38K |
| 97163 | <1% | 343 | $38K | |
| 81001 | <1% | 21,160 | $37K | |
| 77065 | Tomosynthesis, mammo | <1% | 329 | $37K |
| 87081 | <1% | 7,523 | $37K | |
| 86593 | <1% | 9,829 | $36K | |
| 81260 | <1% | 1,153 | $36K | |
| 93320 | <1% | 731 | $36K | |
| 96523 | <1% | 2,003 | $35K | |
| 86787 | <1% | 3,573 | $35K | |
| 84702 | <1% | 6,814 | $35K | |
| H2011 | Crisis intervention service, per 15 minutes | <1% | 129 | $35K |
| 83020 | <1% | 2,713 | $35K | |
| 70498 | <1% | 151 | $34K | |
| 80069 | <1% | 4,297 | $34K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 155 | $34K |
| 97116 | <1% | 959 | $34K | |
| 76870 | <1% | 493 | $33K | |
| 0081A | <1% | 775 | $33K | |
| 73030 | <1% | 1,983 | $32K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,371 | $32K |
| 86704 | <1% | 3,875 | $32K | |
| 84153 | <1% | 2,102 | $31K | |
| 0124A | <1% | 775 | $31K | |
| 99384 | <1% | 827 | $31K | |
| 93325 | <1% | 979 | $31K | |
| 83718 | <1% | 5,096 | $31K | |
| 85007 | <1% | 12,745 | $30K | |
| 91320 | <1% | 616 | $30K | |
| 73130 | <1% | 2,189 | $30K | |
| 73590 | <1% | 1,950 | $30K | |
| 97010 | <1% | 4,242 | $30K | |
| 10060 | <1% | 196 | $30K | |
| 73090 | <1% | 2,147 | $29K | |
| 90681 | <1% | 4,571 | $28K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 278 | $27K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 894 | $27K |
| 72128 | <1% | 231 | $26K | |
| 0082A | <1% | 602 | $26K | |
| 84146 | <1% | 1,384 | $26K | |
| 76885 | <1% | 204 | $25K | |
| 90739 | <1% | 331 | $25K | |
| 99173 | <1% | 13,770 | $25K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 558 | $24K |
| 83550 | <1% | 3,795 | $24K | |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | <1% | 431 | $24K |
| 73560 | <1% | 932 | $24K | |
| 93970 | <1% | 95 | $24K | |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 822 | $24K |
| 97803 | <1% | 1,462 | $24K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,820 | $23K |
| S9484 | Crisis intervention mental health services, per hour | <1% | 192 | $23K |
| S9088 | Services provided in an urgent care center (list in addition to code for service) | <1% | 508 | $23K |
| 82043 | <1% | 5,207 | $23K | |
| J1631 | Injection, haloperidol decanoate, per 50 mg | <1% | 1,740 | $22K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 52 | $22K |
| 80348 | <1% | 3,336 | $21K | |
| 87631 | <1% | 542 | $21K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 427 | $21K |
| 90707 | <1% | 1,971 | $20K | |
| 92551 | <1% | 9,178 | $20K | |
| 80320 | <1% | 8,104 | $20K | |
| 73140 | <1% | 994 | $20K | |
| 90662 | <1% | 753 | $20K | |
| 83540 | <1% | 4,270 | $20K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 332 | $20K |
| 70496 | <1% | 149 | $19K | |
| 73070 | <1% | 1,165 | $19K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 785 | $19K |
| 90620 | <1% | 1,357 | $19K | |
| 76775 | <1% | 485 | $18K | |
| 84460 | <1% | 3,657 | $18K | |
| 82465 | <1% | 5,415 | $18K | |
| 82952 | <1% | 2,035 | $18K | |
| 71250 | <1% | 91 | $18K | |
| 90633 | <1% | 3,232 | $18K | |
| 86880 | <1% | 2,318 | $17K | |
| 73502 | <1% | 710 | $17K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,541 | $17K |
| 96156 | <1% | 481 | $17K | |
| 73100 | <1% | 675 | $17K | |
| 90661 | <1% | 964 | $17K | |
| 83516 | <1% | 1,266 | $17K | |
| 86003 | <1% | 552 | $16K | |
| D1206 | Topical application of fluoride varnish | <1% | 2,063 | $15K |
| 0154A | <1% | 414 | $15K | |
| 83001 | <1% | 843 | $15K | |
| 94060 | <1% | 187 | $15K | |
| 83970 | <1% | 417 | $15K | |
| 90647 | <1% | 3,523 | $15K | |
| 76825 | <1% | 47 | $15K | |
| 90678 | <1% | 252 | $15K | |
| 84484 | <1% | 10,965 | $14K | |
| 86141 | <1% | 2,696 | $14K | |
| 87186 | <1% | 3,469 | $14K | |
| 90716 | <1% | 1,791 | $14K | |
| 99409 | <1% | 178 | $13K | |
| 81229 | <1% | 12 | $13K | |
| 17110 | <1% | 90 | $13K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 253 | $13K |
| 90474 | <1% | 3,264 | $13K | |
| 73080 | <1% | 935 | $13K | |
| 85730 | <1% | 7,676 | $12K | |
| 94729 | <1% | 219 | $12K | |
| 94726 | <1% | 202 | $12K | |
| 86708 | <1% | 1,472 | $12K | |
| 0074A | <1% | 289 | $12K | |
| 73600 | <1% | 567 | $12K | |
| 84402 | <1% | 489 | $12K | |
| 58300 | <1% | 102 | $12K | |
| 90723 | <1% | 2,941 | $11K | |
| 84403 | <1% | 470 | $11K | |
| 73060 | <1% | 905 | $11K | |
| 72100 | <1% | 374 | $11K | |
| 87517 | <1% | 254 | $11K | |
| 88304 | <1% | 430 | $11K | |
| 83002 | <1% | 597 | $11K | |
| 99412 | <1% | 1,101 | $10K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 512 | $10K |
| 82677 | <1% | 418 | $10K | |
| 82274 | <1% | 920 | $10K | |
| J1944 | Injection, aripiprazole lauroxil, (aristada), 1 mg | <1% | 27 | $10K |
| 87522 | Neg quan hep c or qual rna | <1% | 251 | $10K |
| 96167 | <1% | 573 | $10K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 6,317 | $9K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,334 | $9K |
| 73552 | <1% | 593 | $9K | |
| J7300 | Intrauterine copper contraceptive (paragard) | <1% | 14 | $9K |
| 92526 | <1% | 154 | $9K | |
| T2022 | Case management, per month | <1% | 200 | $9K |
| 73620 | <1% | 352 | $9K | |
| 82977 | <1% | 1,647 | $9K | |
| 97165 | <1% | 91 | $9K | |
| D0330 | Panoramic radiographic image | <1% | 403 | $9K |
| 73700 | <1% | 41 | $9K | |
| 80165 | <1% | 1,501 | $9K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 14 | $8K |
| 87338 | <1% | 732 | $8K | |
| 83735 | <1% | 5,363 | $8K | |
| 82627 | <1% | 366 | $8K | |
| 76604 | <1% | 63 | $8K | |
| 82570 | <1% | 2,026 | $8K | |
| 83690 | <1% | 9,142 | $7K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,074 | $7K |
| 86592 | <1% | 1,495 | $7K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 6,099 | $7K |
| 0083A | <1% | 163 | $7K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 206 | $7K |
| 90744 | <1% | 1,986 | $7K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,798 | $7K |
| 90700 | <1% | 1,434 | $7K | |
| 86800 | <1% | 471 | $7K | |
| 88141 | <1% | 308 | $7K | |
| 86735 | <1% | 838 | $6K | |
| 86376 | <1% | 481 | $6K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,261 | $6K |
| D0140 | Limited oral evaluation - problem focused | <1% | 585 | $6K |
| 86336 | <1% | 417 | $6K | |
| 87800 | <1% | 251 | $6K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 7,761 | $6K |
| 84480 | <1% | 674 | $6K | |
| 99402 | <1% | 99 | $6K | |
| 99383 | <1% | 232 | $6K | |
| S9083 | Global fee urgent care centers | <1% | 45 | $6K |
| 84704 | <1% | 403 | $6K | |
| 90656 | <1% | 1,049 | $5K | |
| 84156 | <1% | 1,879 | $5K | |
| 82803 | <1% | 2,297 | $5K | |
| 92083 | <1% | 80 | $5K | |
| 85651 | <1% | 2,150 | $5K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 688 | $5K |
| 86753 | <1% | 499 | $5K | |
| 80321 | <1% | 430 | $5K | |
| 73000 | <1% | 245 | $5K | |
| 86255 | <1% | 433 | $5K | |
| D7210 | Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth | <1% | 97 | $5K |
| 96415 | <1% | 18 | $5K | |
| 84450 | <1% | 1,202 | $5K | |
| 0011A | <1% | 324 | $5K | |
| 82248 | <1% | 1,478 | $5K | |
| 82239 | <1% | 379 | $4K | |
| 87486 | <1% | 285 | $4K | |
| 96040 | <1% | 70 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,364 | $4K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 145 | $4K |
| 85045 | <1% | 1,215 | $4K | |
| Q3014 | Telehealth originating site facility fee | <1% | 611 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,599 | $4K |
| 92610 | <1% | 53 | $4K | |
| 76827 | <1% | 46 | $4K | |
| 73120 | <1% | 149 | $4K | |
| 72170 | <1% | 441 | $4K | |
| 73562 | <1% | 296 | $4K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,117 | $4K |
| 97164 | <1% | 52 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,870 | $4K |
| 91318 | <1% | 574 | $4K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 31 | $4K |
| 84100 | <1% | 2,950 | $3K | |
| 93226 | <1% | 66 | $3K | |
| 92587 | <1% | 129 | $3K | |
| 86705 | <1% | 573 | $3K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 3,749 | $3K |
| 74018 | <1% | 161 | $3K | |
| 87581 | <1% | 285 | $3K | |
| 73200 | <1% | 13 | $3K | |
| 96380 | <1% | 599 | $3K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 38 | $3K |
| 82785 | <1% | 316 | $3K | |
| 77080 | <1% | 131 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,866 | $3K |
| 84436 | <1% | 454 | $3K | |
| 70491 | <1% | 12 | $3K | |
| 0012A | <1% | 151 | $3K | |
| 90694 | <1% | 199 | $3K | |
| 86140 | <1% | 984 | $3K | |
| 69210 | <1% | 38 | $3K | |
| 82670 | <1% | 100 | $3K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 95 | $3K |
| 86038 | <1% | 332 | $3K | |
| 25605 | <1% | 14 | $3K | |
| 86258 | <1% | 163 | $3K | |
| 82784 | <1% | 243 | $3K | |
| 97162 | <1% | 28 | $3K | |
| 99401 | <1% | 57 | $3K | |
| 76813 | <1% | 70 | $3K | |
| 99385 | <1% | 37 | $3K | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 1,098 | $3K |
| 90836 | <1% | 27 | $3K | |
| 29125 | <1% | 31 | $3K | |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 12 | $3K |
| 0003A | <1% | 54 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,079 | $2K |
| 71271 | <1% | 13 | $2K | |
| 80178 | <1% | 672 | $2K | |
| 85379 | <1% | 1,590 | $2K | |
| 90710 | <1% | 707 | $2K | |
| 10120 | <1% | 19 | $2K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 33 | $2K |
| 11981 | <1% | 14 | $2K | |
| 90696 | <1% | 707 | $2K | |
| 93971 | <1% | 36 | $2K | |
| 86231 | <1% | 214 | $2K | |
| 97533 | <1% | 41 | $2K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 39 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,840 | $2K |
| 82550 | <1% | 938 | $2K | |
| 87070 | <1% | 563 | $2K | |
| 96376 | <1% | 936 | $2K | |
| 99382 | <1% | 68 | $2K | |
| 82746 | <1% | 193 | $2K | |
| 92550 | <1% | 64 | $2K | |
| 91319 | <1% | 345 | $2K | |
| 87040 | <1% | 1,276 | $2K | |
| 76814 | <1% | 56 | $2K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 72 | $2K |
| 83498 | <1% | 67 | $2K | |
| 72190 | <1% | 112 | $2K | |
| 11900 | <1% | 12 | $2K | |
| 88342 | <1% | 26 | $2K | |
| 90672 | <1% | 671 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,966 | $2K |
| 96168 | <1% | 158 | $2K | |
| 99188 | <1% | 225 | $2K | |
| 88112 | <1% | 15 | $1K | |
| 92133 | <1% | 24 | $1K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 12 | $1K |
| 82947 | <1% | 259 | $1K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 13 | $1K |
| 0173A | <1% | 149 | $1K | |
| 87045 | <1% | 200 | $1K | |
| 95024 | <1% | 54 | $1K | |
| 82533 | <1% | 74 | $1K | |
| 92025 | <1% | 30 | $1K | |
| 87205 | <1% | 635 | $1K | |
| 81002 | <1% | 784 | $1K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 702 | $1K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 208 | $1K |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 1,342 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,702 | $1K |
| 90623 | <1% | 95 | $1K | |
| 74019 | <1% | 39 | $1K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 15 | $998.13 |
| 83615 | <1% | 348 | $958.73 | |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 34 | $909.32 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,489 | $885.37 |
| 82397 | <1% | 464 | $850.59 | |
| 90473 | <1% | 841 | $842.40 | |
| 99221 | <1% | 13 | $803.57 | |
| 82247 | <1% | 360 | $801.45 | |
| 97124 | <1% | 27 | $798.99 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 712 | $783.75 |
| 87507 | <1% | 29 | $744.24 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 956 | $733.24 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 30 | $681.57 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,292 | $671.79 |
| 0502F | <1% | 1,013 | $656.40 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 157 | $646.18 |
| 84550 | <1% | 181 | $597.16 | |
| 84445 | <1% | 12 | $569.67 | |
| 0073A | <1% | 39 | $523.92 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 961 | $509.74 |
| 92227 | <1% | 80 | $495.30 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 331 | $477.38 |
| 90660 | <1% | 153 | $472.77 | |
| 85018 | <1% | 204 | $467.36 | |
| 85014 | <1% | 210 | $465.60 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 91 | $460.65 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 34 | $457.65 |
| G0008 | Administration of influenza virus vaccine | <1% | 950 | $457.01 |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 12 | $452.99 |
| 93280 | <1% | 26 | $427.53 | |
| 17250 | <1% | 12 | $415.69 | |
| 87116 | <1% | 34 | $401.56 | |
| 72040 | <1% | 12 | $378.79 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 684 | $365.67 |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 41 | $358.46 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,293 | $347.62 |
| 80047 | <1% | 39 | $334.49 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 269 | $334.06 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 2,792 | $322.69 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 147 | $317.13 |
| 82378 | <1% | 16 | $301.20 | |
| 86580 | <1% | 212 | $296.95 | |
| 84305 | <1% | 14 | $296.92 | |
| 84478 | <1% | 171 | $287.39 | |
| J1815 | Injection, insulin, per 5 units | <1% | 452 | $277.48 |
| D0190 | <1% | 1,146 | $272.92 | |
| 82962 | <1% | 609 | $250.34 | |
| 90671 | <1% | 50 | $249.91 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 2,983 | $226.72 |
| 84432 | <1% | 12 | $214.88 | |
| 85244 | <1% | 13 | $206.33 | |
| 87420 | <1% | 111 | $205.96 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 335 | $190.94 |
| 82310 | <1% | 46 | $185.76 | |
| 87206 | <1% | 34 | $184.35 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 524 | $181.40 |
| 84154 | <1% | 13 | $180.55 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,108 | $177.77 |
| 82565 | <1% | 31 | $168.76 | |
| 83605 | <1% | 157 | $168.68 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 77 | $162.17 |
| 84075 | <1% | 63 | $149.06 | |
| 96160 | <1% | 14 | $139.02 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 42 | $129.47 |
| 90381 | <1% | 92 | $128.79 | |
| 90713 | <1% | 40 | $125.31 | |
| 82390 | <1% | 15 | $122.05 | |
| 82103 | <1% | 13 | $107.54 | |
| 84520 | <1% | 29 | $106.84 | |
| 85732 | <1% | 13 | $103.36 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 316 | $95.90 |
| J3230 | Injection, chlorpromazine hcl, up to 50 mg | <1% | 15 | $95.90 |
| 90685 | <1% | 277 | $94.13 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 85 | $89.60 |
| 86430 | <1% | 13 | $83.44 | |
| 82330 | <1% | 67 | $79.57 | |
| 82150 | <1% | 39 | $71.33 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 48 | $63.20 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 132 | $50.78 |
| 99152 | <1% | 16 | $38.71 | |
| 3078F | <1% | 42,022 | $31.47 | |
| 80361 | <1% | 13 | $31.08 | |
| 80354 | <1% | 15 | $31.08 | |
| 80358 | <1% | 21 | $31.08 | |
| 90714 | <1% | 19 | $27.91 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 27 | $26.74 |
| 90380 | <1% | 30 | $25.75 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 144 | $25.66 |
| 3077F | <1% | 4,099 | $25.00 | |
| J3490 | Unclassified drugs | <1% | 12 | $20.52 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 30 | $14.22 |
| 84155 | <1% | 37 | $10.97 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 25 | $9.99 |
| 87075 | <1% | 13 | $9.47 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 20 | $9.20 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 16 | $9.20 |
| 3074F | <1% | 42,330 | $6.47 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 16 | $5.48 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 14 | $2.73 |
| 3075F | <1% | 8,071 | $0.03 | |
| 99499 | 0% | 2,408 | $0.00 | |
| 1159F | 0% | 5,591 | $0.00 | |
| D0191 | 0% | 544 | $0.00 | |
| 99080 | 0% | 1,619 | $0.00 | |
| 96417 | 0% | 15 | $0.00 | |
| 1160F | 0% | 4,291 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 55 | $0.00 |
| 57170 | 0% | 12 | $0.00 | |
| 3080F | 0% | 1,742 | $0.00 | |
| 3079F | 0% | 10,653 | $0.00 | |
| 94760 | 0% | 367 | $0.00 | |
| D1330 | 0% | 356 | $0.00 | |
| 4293F | 0% | 882 | $0.00 | |
| 1220F | 0% | 4,234 | $0.00 | |
| 3044F | 0% | 170 | $0.00 | |
| 1126F | 0% | 14 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKARLIN, MARJI (CHIEF REVENUE OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.